Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001213900-24-076588
Filing Date
2024-09-06
Accepted
2024-09-06 17:03:26
Documents
2
Period of Report
2024-08-29

Document Format Files

Seq Description Document Type Size
1 ownership.html 3  
1 ownership.xml 3 4427
2 POWER OF ATTORNEY ea021374407ex24_oruka.htm EX-24 5481
  Complete submission text file 0001213900-24-076588.txt   11701
Mailing Address 855 OAK GROVE AVE. SUITE 100 MENLO PARK CA 94025
Business Address 855 OAK GROVE AVE. SUITE 100 MENLO PARK CA 94025 650-606-7910
Oruka Therapeutics, Inc. (Issuer) CIK: 0000907654 (see all company filings)

EIN.: 363855489 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)

Mailing Address C/O CYMABAY THERAPEUTICS, INC. 7575 GATEWAY BLVD., SUITE 110 NEWARK CA 94560
Business Address 510-293-8123
Quinlan Paul T (Reporting) CIK: 0001333277 (see all company filings)

Type: 3 | Act: 34 | File No.: 000-22873 | Film No.: 241285149